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Abstract: AIM OF STUDY Venous thromboembolic events (VTEs) are significant complications in
patients with systemic malignancies. Thrombosis risk is poorly defined for patients with brain metastasis,
and available risk calculation scores are not validated for these patients. METHODS We identified 811
patients with brain metastasis followed at our institution and reviewed electronic charts retrospectively
for the occurrence of VTEs, along with candidate risk factors. Risk factors were tested in univariate and
multivariate analyses and finally integrated in a score model for risk estimation. An independent cohort
of 346 patients with brain metastasis was available for validation. RESULTS VTEs were documented
in 97 of 811 patients (12.0%). Primary tumours with high thrombogenicity (p = 0.02, hazard ratio 1.7,
95% confidence interval (CI) = 1.1-2.8), dexamethasone (p = 0.011, hazard ratio 2.27, 95% CI = 1.5-
4.5), chemotherapy (p = 0.005, hazard ratio 3.4, 95% CI = 1.6-7.5), body mass index > 35 kg/m2 (p =
0.002, hazard ratio 3.4, 95% CI = 1.6-7.5) and immobilisation (p = 0.003, hazard ratio 2.4, 95% CI =
1.3-4.3) were confirmed to be independently associated with VTEs. We derived a score model for VTE
risk estimation, the thrombogenic primary, immobilization, chemotherapy, obesity, steroid (PICOS) score
(0-7 points). Receiver-operating characteristic curve analysis demonstrated its prognostic accuracy (area
under the curve [AUC] = 0.71, 95% CI = 0.64-0.77), and its value for the evaluation of VTE risk was
superior to that of other scores such as the Khorana (AUC = 0.51) or CONKO (AUC = 0.52) scores.
The potential value of the PICOS score was confirmed in the validation cohort (AUC = 0.72, 95% CI =
0.63-0.82). CONCLUSIONS The PICOS score may become a helpful tool for the identification of patients
with brain metastasis at high risk for VTEs and for stratification in controlled studies.
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Abstract 
 
AIM OF STUDY: Venous thromboembolic events are significant complications in patients with 
systemic malignancies. Thrombosis risk is poorly defined for patients with brain metastasis, and 
available risk calculation scores are not validated for these patients. 
METHODS: We identified 811 patients with brain metastasis followed at our institution and 
reviewed electronic charts retrospectively for the occurrence of venous thromboembolic events, 
along with candidate risk factors. Risk factors were tested in uni- and multivariate analyses and 
finally integrated in a score model for risk estimation. An independent cohort of 346 patients with 
brain metastasis was available for validation. 
RESULTS: Venous thromboembolic events were documented in 97 of 811 patients (12.0%). 
Primary tumors with high thrombogenicity (p=0.02, Hazard Ratio 1.7, 95% CI 1.1-2.8), 
dexamethasone (p=0.011, Hazard Ratio 2.27, 95% CI 1.5-4.5), chemotherapy (p=0.005, Hazard 
Ratio 3.4, 95% CI 1.6-7.5), BMI > 35 kg/m2 (p=0.002, Hazard Ratio 3.4, 95% CI 1.6-7.5) and 
immobilization (p=0.003, Hazard Ratio 2.4, 95% CI 1.3-4.3) were confirmed to be independently 
associated with VTE. We derived a score model for venous thromboembolic event risk estimation, 
the PICOS (thrombogenic Primary, Immobilization, Chemotherapy, Obesity, Steroids) score (0-7 
points). Receiver Operating Characteristic Curve Analysis demonstrated its prognostic accuracy 
(AUC=0.71, 95% CI 0.64-0.77), and its value for the evaluation of venous thromboembolic event 
risk was superior to that of other scores such as the Khorana (AUC=0.51) or CONKO (AUC=0.52) 
scores. The potential value of the PICOS score was confirmed in the validation cohort (AUC=0.72, 
95% CI 0.63-0.82). 
CONCLUSIONS: The PICOS score may become a helpful tool for the identification of brain 
metastasis patients at high risk for venous thromboembolic events and for stratification in 
controlled studies. 
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Highlights 
- Venous thromboembolic events (VTE) were found in 12% of our patients with brain metastasis 
(BM) 
- Primary, Immobilization, Chemotherapy, Obesity, Steroids (PICOS) are independently 
associated with VTE 
- The PICOS score is superior to established risk models for VTE risk estimation 
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1. Introduction 
Metastases to the central nervous system (CNS) are the most common malignant brain tumors [1] 
and their management is of major relevance with regard to the overall goal of cancer therapy of 
maintaining or improving quality of life [2, 3]. 
Cancer patients frequently suffer from vascular complications, mostly venous thromboembolic 
events (VTE) [4]. Potential risk factors for cancer-associated VTE include comorbidities, notably 
prior VTE, steroid medication, immobilization, and radiotherapy and chemotherapy [4-6]. Khorana 
et al. defined a score for risk estimation of VTE in cancer patients which takes into consideration 
site of cancer, increased platelet and decreased leukocyte count as well as decreased hemoglobin 
level and overweight. It is broadly used for clinical decision making towards thrombosis 
prophylaxis [6]. The Khorana score was further adjusted by replacing adipositas by Eastern 
Cooperative Oncology Group (ECOG) performance status (CONKO score [7]), or inclusion of 
serum markers (D-dimers and soluble P-selectin, Vienna CATS score [8]) or specification of 
chemotherapy (gemcitabine or platinum-based therapy, PROTECHT score [9]). However, none of 
these scores has been validated for patients with brain metastases (BM), and studies on several 
tumor entities have demonstrated the limitations of the Khorana score for risk estimation [10]. 
The management of VTE in BM patients has also remained controversial, both because of risk of 
hemorrhage upon institution of, and unclear benefit from, primary or secondary thrombosis 
prophylaxis and anticoagulant therapy [11, 12]. Retrospective studies report a limited risk of 
intracranial hemorrhage of BM patients on anticoagulation [13, 14], but prospective data in BM 
patients are lacking and current treatment recommendations for patients with BM [3] do not cover 
vascular complications in depth. Here, we sought to define the VTE risk profile of BM patients in a 
well-characterized discovery cohort of 811 as well as a validation cohort of 346 subjects and 
derive implications for VTE management. 
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2. Patients and methods 
 
2.1 Patients 
For the discovery cohort, patients diagnosed with and treated for BM were identified by review of 
the electronic chart system of the University Hospital Zurich (USZ). Interrogation of the electronic 
chart system (search term “brain metastasis”) yielded 1453 candidate adult patients, 811 patients 
with BM from solid tumors (patients with non-solid tumors, e.g. lymphoma, were excluded) were 
finally included (Figure 1). Follow-up was documented in the electronic chart, until death 
information was obtained in 628 of 811 BM patients (77.4%). Median follow-up of the remaining 
183 of 811 patients (22.6%) which were later censored, was 15 months (95% CI 11-22). An 
external validation cohort of 346 patients from the University of Vienna was provided by authors 
ASB, RL and MP, data were collected according to local regulations. Follow-up until death was 
obtained for 231 of 346 patients (66.8%), median follow-up of the remaining 115 of 346 patients 
(33.2%) was 12.9 months (95% CI 10-18 months). This study was performed according to the 
Declaration of Helsinki and approved by the local cantonal ethics committee for the discovery 
cohort (KEK-ZH-Nr. 2018-00192) and for the validation cohort (Ethics number 1375/2018). 
 
2.2 Variables 
Vascular events were classified as thrombotic, including deep vein thrombosis (DVT), pulmonary 
embolism (PE), and cerebral venous thombosis (CVT) according to documentation in the 
electronic charts by the treating clinicians. The items of the Khorana score [6], primary tumor (very 
high risk: stomach, pancreas; high risk: lung, lymphoma, gynecologic, bladder, testicular, renal cell 
cancer (RCC), platelet (>350,000/l) and leukocyte count (>11,000/l), hemoglobin (<10 g/dl) 
levels as well as body mass index (BMI) >35 kg/m2 and the ECOG performance status [15] were 
assessed at the time of BM diagnosis. Steroid intake was assessed at the time of BM diagnosis 
and 12 weeks later. Furthermore, data on other comorbidities and chemo- or radiotherapy after 
VTE in patients with brain metastases 
Page 7 of 23 
diagnosis of BM, treatment with bevacizumab or immobilization by hemiparesis were captured in 
the discovery cohort. Severity grades of VTE were determined according to Common Terminology 
Criteria for Adverse Events (CTCAE) 
(https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ docs/ 
CTCAE_v5_Quick_Reference_8.5x11.pdf) based on information from medical files. 
 
2.3 Statistical methods 
For univariate analysis, unpaired nominal data were assessed by the chi-square test and linearly 
scaled data by the Mann-Whitney U test where appropriate. To exclude bias from diverging 
survival, a stepwise Cox Hazard model with time to first VTE as outcome measure was applied for 
multivariate analysis of factors possibly associated with VTE, either identified in univariate 
analyses or previously described in the literature. Survival times were estimated using the Kaplan-
Meier method. The items of the established Khorana and the CONKO score were integrated as 
possible confounding variables. The score model was further evaluated by assessment of the area 
under the receiver-operating characteristic (ROC) curves employing IBM SPSS statistics ®.  
No discrimination is reflected by an area under the curve (AUC) of 0.5, a perfect discrimination by 
an AUC of 1, an AUC of 0.7 is widely accepted as threshold for a clinically relevant discrimination 
capability of a score [16]. The p-values in the ROC analysis test the null hypothesis for each score, 
whether the area under the curve really equals 0.50 (reference). 
For comparison of scores, patients with missing data were omitted from respective analyses. 
Statistical analysis was performed by authors FW and MCN using IBM SPSS statistics ®, Version 
22 (IBM Co., Armonk, NY, USA) and GraphPad Prism software, version 7.0 (La Jolla, CA, USA). 
Significance levels for two-sided p-values were set at p<0.05 for significant and p<0.01 for highly 
significant results.
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3. Results 
 
3.1 Co-factors and outcomes of VTE 
Figure 1 shows the patient selection process, patient characteristics are summarized in Table 1 in 
the discovery cohort. Altogether, 12% of patients were diagnosed with at least one VTE after the 
diagnosis of BM, predominantly DVT and PE (Figure 2A). The median latency from diagnosis of 
BM to first VTE was 73 days (95% CI 41-126). The sequence of multiple VTE is outlined in 
Appendix A. 
The risk for VTE was 6% (50 of 811 patients) within the first 3 months, 8% (61 of 811 patients) 
within 6 months, and 9% (74 of 811 patients) within one year after diagnosis of BM. VTE was 
detected within 24 h before diagnosis of BM in 2 of 811 patients, one of them with symptomatic 
DVT, one with asymptomatic PE. 
Information on VTE prophylaxis prior to the first VTE was available for 91 of 97 patients; 82 
patients (90%) had no prophylaxis at all. Two patients (2%) were already on oral anticoagulation 
with vitamin K antagonists due to prior diagnosis of atrial fibrillation and 7 patients (8%) were on 
prophylactic low weight molecular heparin (LWMH). After the first VTE, 17 of 82 patients (21%) 
with no prior prophylaxis received no further VTE treatment; 16 patients (20%) were placed on oral 
anticoagulants and 49 patients (59.8%) were placed on therapeutic dose LWMH. Before the 
second VTE, anticoagulation had been stopped in some cases: anticoagulation in 4 of 6 patients 
(67%) and therapeutic dose LWMH 5 of 11 patients (46%), probably because of perceived 
increased bleeding risk. In turn, one of three patients without prophylaxis after the first thrombosis 
was placed on LWMH after the second VTE. 
In the discovery cohort, 568 of 811 patients were operated for BM. Of those, 75 experienced a 
VTE (13%), with no information on the exact date in 6 of 75 patients; in the remaining 69 patients, 
VTE occurred predominantly in the postoperative phase within 4 weeks or later (Figure 2B). 
Median latency from surgery to first VTE was 28 days (95% CI 10-82). Overall survival in the 
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discovery cohort was 11 months (95% CI 8.8-11.2 months). There was no difference between 
patients with (10 months, 95% CI 8.6-11.4 months) or without VTE (12 months, 95% CI 9.1-14.9 
months; p=0.774, Log-Rank test). Symptoms from and outcomes of VTE are considered in 
Appendix B and Figure A.1. In the validation cohort, at least one VTE was diagnosed in 38 of 346 
patients (11.0%) with up to four VTE after diagnosis of BM (see Table A.1 for patient 
characteristics). The rate of operated patients in the validation cohort was lower than in the 
discovery cohort (26.6% vs. 70.0%, Table1 and Table A.1). 
 
3.2 Identification of risk factors for cancer related thrombosis in BM patients 
The overall rate of VTE in the discovery cohort was 12% across all tumor types. The highest 
incidence was found for patients with cancer from unknown primary tumor (CUP, 24%), lung 
(13%) and RCC (21%) (Table 1). Patients with history of VTE prior to diagnosis of BM had a 
higher rate of VTE in the later course of disease (p=0.052, Table 1). There was a significant 
association between BM from CUP compared to other patients and risk of VTE (p=0.008, Chi-
square test), but no association was found for patients with other primary tumors (Table 1). We 
then clustered tumor entities with higher (including CUP, lung carcinoma and RCC) and with lower 
VTE rates (melanoma, breast cancer, gastrointestinal cancer, other) from the discovery cohort. 
These associations of tumors and VTE rates were in line with previous reports [6, 17]. There was 
a significant difference in VTE rate between tumors with high (61 of of 406 patients, 15%) and low 
(36 of 405 patients, 9%) thrombogenicity (p=0.007, Chi-Square test). 
On univariate analysis in the discovery cohort, begin or continuation of chemotherapy after 
diagnosis of BM was associated with VTE (p=0.000062, Table 1). Neither for radiotherapy to the 
brain (p=0.830) nor for treatment with bevacizumab (p=0.146) such association with VTE was 
observed (Table 1). There was a trend towards association of VTE and dexamethasone intake at 
the time of diagnosis of BM (p=0.063) and 12 weeks afterwards (p=0.052, Table 1). Furthermore, 
immobilization by e.g. severe hemiparesis or other neurological deficits was associated with VTE 
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(p=0.035, Table 1). Adipositas WHO grades at the time of diagnosis were not associated with VTE 
rate. We next performed an analysis of patients with WHO grade II and III adipositas since a BMI > 
35 kg/m2 has been reported to be associated with an increased VTE risk [6]. Such patients 
showed indeed a higher rate of VTE, albeit this subgroup was very small (p=0.006, Table 1).  
 
In the validation cohort, percentages of patients with VTE were evenly higher in individuals 
exposed to the risk factors identified in the discovery cohort, although this was statistically not 
significant for all of them (thrombogenic primary tumor: p=0.061; immobilization: p=0.00001; 
chemotherapy: p=0.228; obesity: p=0.799; dexamethasone p=0.004; all Chi-square test; see also 
Table A1). For consideration on the effect of thrombosis prophylaxis in the discovery cohort see 
Appendix C. 
 
We tested furthermore the diagnostic accuracy of the Khorana score [6] at the time of diagnosis of 
BM in the discovery cohort. Except for BMI > 35 kg/m2 (p=0.006, Table 1), none of its items were 
associated with VTE risk (tumor histology: p=0.309, Chi-square test; TC: p= 0.579, LC: p=0.409, 
Hb: p=0.889, all Mann-Whitney U Test, data not shown) in univariate analysis. In multivariate 
analysis employing a Cox regression model, none of the score items showed an independent 
association with VTE risk (Table A.2). However, the Khorana score could be calculated for 498 of 
811 patients and the CONKO score for 535 of 811 patients only in the discovery cohort. 
 
3.3 Multivariate analysis 
The items of the Khorana score and factors associated with the incidence of thrombotic events in 
univariate analysis were further explored in by a Cox Hazard model. Co-variates for VTE were 
high thrombogenic primary tumors, chemotherapy, dexamethasone intake at the time of diagnosis, 
immobilization, and high BMI (>35 kg/m2). Primary tumors with high thrombogenicity (p=0.020, HR 
1.7, 95% CI 1.1-2.8), dexamethasone intake (p=0.011, HR 2.3, 95% CI 1.5-4.5), chemotherapy 
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after diagnosis of BM (p=0.005, HR 3.4, 95% CI 1.6-7.5), BMI > 35 kg/m2 (p=0.002, HR 3.4, 95% 
CI 1.6-7.5) and immobilization (p=0.003, HR 2.4, 95% CI 1.3-4.3) were confirmed to be 
independently associated with VTE in the discovery cohort (Table 2). In the validation cohort, 
immobilization (p=0.001, HR 6.2, 95% CI 2.7-14.2) and dexamethasone intake at the time of 
diagnosis (p=0.046, HR 2.3, 95% CI 1.1-5.0) were confirmed to be independently associated with 
VTE. A trend was shown for thrombogenic primary tumors (p=0.225, HR 1.7, 95% CI 0.7-4.3) and 
chemotherapy (p=0.146, HR 2.0, 95% CI 0.8-4.8). Only 14 patients with a BMI >35 kg/m2 were 
available for evaluation, which limits the statistical analysis (p=0.448, HR 1.8, 95% CI 0.4-7.9, 
Table A.3). 
 
3.4 Development of a new score for VTE risk estimation: the PICOS score 
These factors that were independently associated with VTE in the discovery cohort were used to 
derive a model for VTE prediction. Scores were calculated according to HR values (HR<2 scores 1 
point; HR=2-3 scores 2 points; HR>3 scores 3 points): dexamethasone intake 2 points, 
chemotherapy 1 point, thrombogenic primary 1 point, immobilization 2 points, BMI > 35 kg/m2 3 
points. The PICOS (thrombogenic Primary, Immobilization, Chemotherapy, Obesity, Steroids) 
score could be calculated for 671 patients. Post-hoc testing revealed that the occurrence of VTE 
increased with the score result (Figure 3A,B). We next performed a Receiver Operating 
Characteristic (ROC) Curve Analysis to assess for sensitivity and specificity (Figure 3C). We found 
an AUC of 0.71 (95% CI 0.64-0.77, p=0.0000035), which reflects the power of our score. We then 
tested the PICOS score against the established Khorana and the CONKO score in the discovery 
cohort in the subgroup of patients for which all respective score items were available (n=372 of 
811 patients). Here, we found an AUC of 0.69 (95% CI 0.60-0.78, p=0.000280) for the PICOS 
score compared to an AUC of 0.51 (95% CI 0.44-0.59, p=0.761) for the Khorana score or an AUC 
of 0.52 (95% CI 0.45-0.59, p=0.646) for the CONKO score (Figure 4). The discrimination capability 
of our score was significant for VTE within the first 3 months (AUC=0.65, 95% CI 0.56-0.73, 
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p=0.000010), 6 months (AUC=0.67, 95% CI 0.59-0.74, p=0.000010) and 12 months (AUC=0.67, 
95% CI 0.61-0.73, p=0.00001, all ROC analysis in the discovery cohort), although AUC were just 
below the threshold of 0.7. Evenly, there was no significant difference between operated and non-
operated patients in the discovery cohort (non-operated patients: AUC=0.704, p=0.01; operated 
patients: AUC=0.67, p=0.00007). In the validation cohort, we found an AUC of 0.72 (95% CI 0.63-
0.82, p=0.000065, Figure 3D) for the PICOS score. 
 
4. Discussion 
Cancer-associated VTE are frequent in patients with systemic malignancies and associated with 
impaired quality of life and unfavorable outcome [4, 18]. In contrast to cancer patients with 
extracranial tumor load only [18, 19], the risk profile for VTE in BM patients is poorly defined. 
Here we provide data on the incidence of VTE in a well-defined cohort of 811 BM patients. We 
observed an overall VTE rate of 12% from diagnosis of BM until death in the discovery cohort and 
of 9% within the first year, whereas VTE incidence for patients with extracranial systemic cancer 
varies between 3% and 12% [20]. Findings in an independent external validation cohort (n=346 
patients) were similar with a VTE rate of 11% from diagnosis of BM until death. 
Our dataset suggests that the Khorana Thromboembolic Risk Score, a broadly applied tool for 
estimation of thrombosis risk in cancer patients [4] and its adapted version, the CONKO score, are 
not valid for BM patients. Only high BMI was associated with thrombosis, but not other score items 
(Table A.1). Notably, primary tumors for which Khorana et al. reported the highest thrombogenicity 
(pancreas and stomach cancer), were underrepresented here because they rarely cause BM [1]. 
The accuracy of  scores for risk estimation, including the Khorana Score, in other independent 
patient data sets is limited and often fails confirmation in subgroups or specific cancer entities [21]. 
Therefore, the specific risk profile for VTE in BM patients warranted further investigation. 
Exploration for other, BM-specific risk factors revealed a group of primary tumors (lung cancer, 
CUP, renal cell cancer), chemotherapy, immobilization and dexamethasone as independently 
associated with VTE (Table 1 and Table 2). Although the rate of patients with VTE was higher if 
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they were exposed to the risk factors identified in the discovery cohort, not all of them were 
statistically confirmed, probably because the multivariate analysis was underpowered due to the 
limited number of patients. This was mainly true for obesity, and its re-evaluation as a risk factor 
for VTE in BM patients should be subject of future investigations. 
The association of CUP and thrombosis concurs with the rate of 10% of all cancer patients having 
a history of preceding VTE without other risk factor even years ago [22]. Other putative risk 
factors, including radiotherapy or administration of bevacizumab, were not associated with VTE 
here, however, the number of patients receiving bevacizumab was low. 
In contrast to a previous study [23] which reported a thrombosis risk of 20% in the postoperative 
phase, the majority of VTE was not associated with surgery here. This might be explained by the 
lower rate of perioperative thrombosis prophylaxis in the latter study (53% of patients) [23] 
whereas prophylaxis was administered to at least 66.0% of our patients. As a limitation of our 
study, reporting on thrombosis prophylaxis during hospitalization in the discovery cohort was 
possibly incomplete in older files from our cohort, and the rate of thrombosis prophylaxis might 
have been even higher. 
The improved OS of 11 months in the discovery cohort compared to studies from the late 1990s 
(e.g. 4.4 months [24]) might reflect the advance in therapeutic options of BM patients in the last 
two decades and may provide an explanation why we encountered more thrombotic events in the 
later course of the disease (Figure 2). Altogether, the impact of surgery and perioperative 
prophylaxis on VTE risk could not be definitively determined in our cohort. 
Based on the results from multivariate testing in the discovery cohort (Table 2), we developed a 
score model for VTE risk estimation, the PICOS score, that accounts for dexamethasone therapy 
(2 score points), chemotherapy after diagnosis of BM (1 score point), immobilization (2 score 
points), BMI > 35 kg/m2 (3 score points) and thrombogenicity of the primary tumor (1 score point) 
(Figure 3). Post-hoc calculation of this score confirmed a significant association with VTE for serial 
points in time. ROC analysis revealed an AUC of 0.71 in the discovery cohort and 0.72 in the 
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validation cohort, indicating a clinically significant discrimination capability of the PICOS score, 
superior to the Khorana and CONKO scores (Figure 4). 
Limitations of our study include its retrospective nature, incomplete data for some items, and the 
over-representation of patients operated for BM in the discovery cohort which does not reflect the 
overall population of patients with BM. However, the rate of VTE and the prognostic accuracy of 
the PICOS score were confirmed in the validation cohort, in which only 26% of patients were 
operated. 
Prospective controlled trials on primary thrombosis prophylaxis in BM patients would be needed to 
assess whether this might prevent VTE-associated hospitalization or mortality. However, BM 
patients are mostly excluded from clinical trials assessing thrombosis risk and prevention in cancer 
patients (e.g. [25]), despite growing evidence that even full anticoagulation therapy is safe [26]. 
Based on the findings from our analysis, we conclude that there are subgroups of patients with 
increased risk for thromboembolic events who might benefit from vigorous prophylaxis and, if 
necessary, anticoagulation. 
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Conclusions  
VTE are frequent complications in BM patients and are associated with increased morbidity and 
hospitalization rates. Optimal management remains to be defined. We propose a score (PICOS) 
that was confirmed in an independent validation cohort and might help to identify patients with 
increased VTE risk. Prospective trials should test its value to stratify for VTE risk in BM patients 
which may allow the PICOS score to become a valuable and validated tool for clinical decision 
making. 
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Figure legends 
 
Figure 1: Consort chart. 
The consort chart shows the selection path for patients from the discovery cohort included in this 
study. The upper part documents the preselection process to identify all patients with BM from 
solid tumors and subjects excluded from further analysis. The lower part shows how many patients 
were included in our analysis. 
 
Figure 2: Incidence of VTE and association with surgery. 
A. The number of patients (y-axis) with the respective VTE (x-axis) are shown as bar plots for the 
discovery cohort. B. Patient numbers (y-axis) are shown for different time points after surgery for 
BM (x-axis). Stacked bar plots show absence (black) versus presence (grey) of VTE. ECT=other 
extracranial thrombosis; DVT=deep vein thrombosis; PE=pulmonary embolism; CVT=cerebral 
venous thrombosis. 
 
Figure 3: The PICOS score for estimation of VTE risk. 
A,B. Bar plots show the absolute number (A) and percentage (B) of patients (y-axis) and score 
results (x-axis) for the discovery cohort. The lower part of each stacked column (black) depicts 
patients without VTE compared to those with VTE in the upper part (grey part). C,D. The receiver-
operating characteristic curves are shown for the PICOS score (dashed black line) for the 
discovery (C) and the validation (D) cohort. A reference line indicates an AUC of 0.5 (continuous 
black line). AUC and p values as well as the 95% CI are indicated. 
 
Figure 4: Comparison of the PICOS score and other scores for estimation of VTE risk. 
Receiver-operating characteristic curves are shown for the PICOS score, the CONKO score and 
the Khorana score for the discovery cohort. A straight reference line indicates an AUC of 0.5 
(continuous black line). AUC and p values as well as the 95% CI as indicated. 
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Tables 
Table 1: Patient characteristics stratified for absence versus presence of VTE in the 
discovery cohort. 
The results of review of medical files are shown. The first column depicts the respective 
characteristics item, with main items in bold letters and sub-characters in normal letters. The 
second column shows overall values for all patients, values as indicated. Percentages for sub-
items reflect their fraction compared to the whole entity of a main item. The third and fourth 
columns show the fraction of patients without and with VTE, marked in italic. Percentages refer to 
the fraction of patients with or without VTE for each item. 
 
Table 2: Multivariate analysis on candidate risk factors for VTE in the discovery cohort. 
The results of multivariate testing of candidate risk factors for VTE are shown, which were 
calculated employing a Cox Hazard model. The first column depicts the respective candidate 
factor, the second one the two-sided p-values, the third column the respective Odds ratios 
following 95% CI in the fourth and fifth column. 
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Supplementary material 
Figure A.1: Outcomes of VTE in the discovery cohort. 
A, B. The number of patients (y-axis) and the respective type of VTE (x-axis) are shown as bar 
plots. In A, stacked bar plots show the method that first detected the respective VTE: CT scan of 
the lung (black), duplex ultrasound (dark grey) or other diagnostic methods (e.g. CT of the brain 
for detection of CVT, dark grey). B shows accordingly the fraction of patients with symptomatic 
(black) or asymptomatic VTE (grey). C,D.. The number of patients (y-axis) and the respective 
number of VTE over time (x-axis) are shown as bar plots. In C, stacked bar plots show whether 
patients with new diagnosis or subsequent relapse of VTE were treated as outpatients (black) or 
inpatients (grey). In D, stacked bar plots show fractions of survivors (grey) versus indivduals with 
VTE-associated death (black) from new or relapsing VTE. 
 
Table A.1: Patient characteristics stratified for absence versus presence of VTE in the 
validation cohort. 
The results of review of medical files are shown. The first column depicts the respective 
characteristics item, with main items in bold letters and sub-characters in normal letters. The 
second column shows overall values for all patients, values as indicated. Percentages for sub-
items reflect their fraction compared to the whole entity of a main item. The third and fourth 
columns show the fraction of patients without and with VTE, marked in italic. Percentages refer to 
the fraction of patients with or without VTE for each item. 
 
Table A.2: Multivariate analysis on association between score items of the Khorana Score, 
the CONKO Score and VTE in the discovery cohort. 
Association of items of the Khorana score [6] and VTE was tested in a multivariate a Cox Hazard 
model with time to first VTE as outcome measure. Column one shows the respective score items, 
the following columns adjusted two-sided p-values, odds ratios with 95% CI. BMI=body mass 
VTE in patients with brain metastases 
Page 23 of 23 
index; primary=primary tumor; Hb=hemoglobin; TC=thrombocyte count; LC=leukocyte count; 
ECOG=Eastern Co-operative Oncology Group score. 
 
Table A.3: Multivariate analysis on candidate risk factors for VTE in the validation cohort. 
The results of multivariate testing of candidate risk factors for VTE are shown, which were 
calculated employing a Cox Hazard model. The first column depicts the respective candidate 
factor, the second one the two-sided p-values, the third column the respective Odds ratios 












BM diagnosis confirmed by:
 - surgery  N=568
 - CT or MRI N=243



















































































AUC 0.71 (95%CI 0.64-0.77)



































































PICOS:  AUC=0.69 (95% CI 0.60-0.78)
CONKO: AUC=0.52 (95% CI 0.45-0.59)
Khorana: AUC=0.51 (95% CI 0.44-0.59)
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No VTE (n=714, 
88.0%) 




Sex (m/f) 428/383 374/340 54/43 0.543a 
Age, median (range)  60.7 (19.3-90.1) 60.8 (19.3-90.1) 59.7 (33.1-83.6) 0.158b 
Number of BM, median (range)  2 (1-64) 2 (1-64) 2 (1-22) 0.730 b 
KPS, median (range) 80 (40-100) 80 (40-100) 80 (40-100) 0.718b 
Primary tumor, n (%)   
cancer of unknown primary tumor 45 (5.5) 34 (75.6) 11 (24.4) 0.008 a 
lung cancer 333 (41.1) 289 (86.8) 44 (13.2) 0.359 a 
melanoma 144 (17.8) 133 (92.4) 11 (7.6) 0.078 a 
breast cancer  100 (12.3) 89 (89.0) 11 (11.0) 0.752 a 
renal cell cancer  28 (3.5) 22 (78.6) 6 (21.4) 0.116 a 
gastrointestinal cancer  65 (8.0) 59 (90.8) 6 (9.2) 0.479 a 
other  96 (11.8) 88 (91.7) 8 (8.3) 0.243 a 
Prior vascular event, n (%)   0.617 a 
none  677 (83.5) 75 (89.0) 75 (11.0)  
ischemic stroke 13 (1.4) 10 (76.9 3 (23.1)  
subdural hematoma  2 (0.2) 2 (100) 0 (0)  
Intracranial hemorrhage 1 (0.1) 1 (100) 0 (0)  
deep venous thrombosis  28 (3.5) 22 (78.6) 6 (22.4)  
myocardial infarction  19 (2.3) 16 (84.2) 3 (15.8  
peripheral artery disease  25 (3.1) 22 (88.0) 3 (12.0)  
pulmonary embolism  14 (1.7) 11 (78.6) 3 (21.4)  
other vascular events 6 (0.7) 6 (100) 0 (0)  
multiple events 26 (3.2) 22 (84.6) 4 (15.4)  
History of VTE, n (%)     
no 769 (94.8) 681 (88.6) 88 (11.4) Ref. 
yes 42 (5.2) 33 (78.6) 9 (21.4) 0.052 a 
Smoking, n (%)     
no 250 (36.8) 221 (88.4) 29 (11.6) Ref. 
yes 429 (63.2) 375 (87.4) 54 (12.6) 0.705 a 
no information 132  
pack years (smokers only), median (range) 40 (1-100) 40 (1-150) 40 (2-100) 0.424b 
Vascular prophylaxis at BM diagnosis, n (%)    0.107 a 
none 610 (75.3) 547 (89.7) 63 (10.3) 0.099 a 
acetylsalicylic acid 96 (11.9) 78 (81.3) 18 (18.8) 0.222 a 
clopidogrel 5 (0.6) 4 (80.0) 1 (20.0) 0.548 a 
acetylsalicylic acid+clopidogrel 11 (1.4) 10 (90.9) 1 (9.1) 0.764 a 
vitamin K antagonist 27 (3.3) 23 (85.2) 4 (14.8) 0.617 a 
new oral anticoagulant 9 (1.1) 9 (100.0) 0 (0.0) 0.271 a 
low weight molecular heparine 47 (5.8) 40 (85.1) 7 (14.9) 0.548 a 
antiplatelet drug + (new) oral anticoagluant 5 (0.6) 2 (40.0) 3 (60.0) 0.088 a 
incomplete file 1  
Brain irradiation after BM diagnosis, n (%)     
no  87 (11.2) 76 (87.4) 11 (12.6) Ref. 
yes 692 (88.8) 610 (88.2) 82 (11.8) 0.830 a 
incomplete file 32  
Chemotherapy after BM diagnosis, n (%)     
no  420 (52.0) 388 (92.4) 32 (7.6) Ref. 
yes 387 (48.0) 322 (83.2) 65 (16.8) <0.001 a 
incomplete file 4  
Brain surgery after BM diagnosis, n (%)     
no 243 (30.0) 220 (91.3) 21 (8.7) Ref. 
yes 568 (70.0) 493 (86.8) 75 (13.2) 0.071 a 
Bevacizumab treatment, n (%)     
no 760 (95.5) 673 (88.6) 87 (11.4) Ref. 
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yes 36 (14.5) 29 (80.6) 7 (19.4) 0.146 a 
incomplete file 15  
Dexamethasone treatment, at diagnosis n (%)     
no 74 (9.6) 70 (94.6) 4 (5.4) Ref. 
yes 695 (91.4) 606 (87.2) 89 (12.8) 0.063 a 
incomplete file 42  
Dexamethasone treatment, after 12 weeks  
n (%) 
  
no 173 (54.6) 145 (83.8) 28 (16.2) Ref. 
yes 144(45.4) 108 (76.2) 36 (23.8) 0.052 a 
incomplete file 494  
Immobilization n (%)     
no 727 (89.6) 646 (88.9) 81 (11.1) Ref. 
yes 84 (10.4) 68 (81.0) 16 (19.0) 0.035 a 
WHO adipositas grades n(%)     
underweight (BMI<18.5 kg/m2) 53 47 (88.7) 6 (11.3 0.980 a 
normal (BMI 18.5-24.9 kg/m2) 380 338 (88.9) 42 (11.1) 0.667 a 
pre-adiopositas (BMI 25.0-29.9 kg/m2) 183 162 (88.5) 21 (11.5) 0.956 a 
adipositas grade I (BMI 30.0-34.9 kg/m2) 64 55 (85.9) 9 (14.1) 0.882 a 
adipositas grade II (BMI 35.0-39-9 kg/m2) 13 9 (69.2) 4 (30.8) 0.110 a 
adipositas grade III (BMI>40kg/m2) 10 7 (70.0) 3 (30.0) 0.236 a 
incomplete file 108  
BMI n (%)     
BMI<35 kg/m2 680 (96.7) 602 (88.5) 78 (11.5) Ref. 
BMI>35 kg/m2 23 (3.3) 16 (69.6 7 (30.4) 0.006 a 
incomplete file 108  
*Results of statistical testing, indicating p-values. Significant values are highlighted with bold letters, the respective 
statistical test is indicated with superscript letters. a = Chi square test; b = Mann-Whitney U test. 
 








* The results of multivariate testing of candidate risk factors for VTE are shown, which were calculated employing a Cox Hazards 
model. The first column depicts the respective candidate factor, the second one the two-sided p-values, the third column the 
respective Hazard Ratios following 95% CI in the fourth and fifth column. 
 
Candidate factors p= Hazard Ratio 95% CI 
Lower Upper 
BMI (>35 kg/m2) 0.002 3.4 1.6 7.5 
primary tumor (lung cancer, RC or CUP)  0.020 1.7 1.1 2.8 
dexamethasone intake 0.011 2.3 1.5 4.5 
chemotherapy after BM diagnosis 0.005 3.4 1.6 7.5 
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No VTE (n=308, 
89.0%) 




Sex (m/f) 178/168 158/150 20/18 0.877a 
Age, median (range)  67.0 (27.7-91.7) 67.3 (27.7-91.7)) 64.7 (31.4-89.0) 0.745b 
Number of BM, median (range)  2 (1-15) 2 (1-15) 2 (1-12) 0.670 b 
KPS, median (range) 80 (40-100) 80 (40-100) 70 (30-100) 0.331b 
Primary tumor, n (%)   
cancer of unknown primary tumor 20 (5.8) 13 (65.0) 7 (35.0) <0.001 a 
lung cancer 178 (51.4) 159 (89.3) 19 (10.7) 0.850 a 
melanoma 57 (16.5) 51 (89.5) 6 (10.5) 0.904 a 
breast cancer  63 (18.2) 61 (96.8) 2 (3.2) 0.028 a 
renal cell cancer  28 (8.1) 24 (85.7) 4 (14.3) 0.560 a 
Thrombogenic primary (cancer of unknown 
primary tumor, lung or renal cell cancer), n (%) 
   
0.061 a 
no 120 (34.7) 112 (93.3) 8 (6.7)  
yes 226 (65.3) 196 (86.7) 30 (13.3)  
Brain irradiation after BM diagnosis, n (%)   
no  39 (11.3) 32 (82.1) 7 (17.9) Ref. 
yes 307 (88.7) 276 (89.9) 31 (10.1) 0.140 a 
Chemotherapy after BM diagnosis, n (%)     
no  147 (42.7) 135 (91.8) 12 (8.2) Ref. 
yes 197 (57.3) 173 (87.8)) 24 (12.2) 0.228 a 
incomplete file 2  
Brain surgery after BM diagnosis, n (%)     
no 254 (73.4) 225 (88.6) 29 (11.4) Refa 
yes 92 (26.6) 83 (90.2) 9 (9.8) 0.667 a 
Dexamethasone treatment, at diagnosis n (%)  
no 218 (63.7) 204 (93.6) 14 (6.4)  
yes 124 (36.3) 104 (83.9) 20 (16.1) 0.004 a 
incomplete file 4  
Immobilization n (%)     
no 282 (81.5) 261 (92.6) 21 (7.4) Ref. 
yes 64 (18.5) 47 (73.4) 17 (26.6)) <0.001 a 
WHO adipositas grades n(%)  0.936 a 
underweight (BMI<18.5) 17 16 (94.1) 1 (5.9)  
normal (BMI 18.5-24.9 kg/m2) 134 117 (87.3) 17 (12.7)  
pre-adiopositas (BMI 25.0-29.9 kg/m2) 97 84 (86.6) 13 (13.4)  
adipositas grade I (BMI 30.0-34.9 kg/m2) 35 32 (91.4) 3 (8.6)  
adipositas grade II (BMI 35.0-39-9 kg/m2) 7 6 (85.7) 1 (14.3)  
adipositas grade III (BMI>40kg/m2) 7 6 (85.7) 1 (14.3)  
incomplete file 49  
BMI n (%)   
BMI<35 kg/m2 283 (95.4) 249 (88.0) 34 (12.0) Ref. 
BMI>35 kg/m2 14 (4.7) 12 (85.7) 2 (14.3) 0.799 
incomplete file 49  
*Results of statistical testing, indicating p-values. Significant values are highlighted with bold letters, the respective 
statistical test is indicated with superscript letters. a = Chi square test; b = Mann-Whitney U test. 
 
Table A.2: Multivariate analysis on association between score items of the Khorana Score, 











* Association of items of the Khorana score (Khorana et al., 2008) and VTE was tested in a multivariate a Cox Hazard model with time 
to first VTE as outcome measure. Column one shows the respective score items, the following columns adjusted two-sided p-values, 
Hazard Ratios with 95% CI. BMI=body mass index; primary=primary tumor; Hb=hemoglobin; TC=thrombocyte count; LC=leukocyte 
count; ECOG= Eastern Co-operative Oncology Group score. 
 
Items of the Scores  
(Khorana et al. 2008) 
(Pelzer et al. 2008) p= Hazard Ratio 
95%CI 
Lower Upper 
BMI 0.90 1.01 0.22 4.59 
primary 0.70 1.09 0.69 1.74 
Hb 0.52 1.39 0.51 3.76 
TC 0.36 0.72 0.36 1.45 
LC 0.56 1.17 0.68 2.03 
ECOG 0.80 1.08 0.63 1.93 








* The results of multivariate testing of candidate risk factors for VTE are shown, which were calculated employing a Cox Hazards 
model. The first column depicts the respective candidate factor, the second one the two-sided p-values, the third column the 
respective Hazard Ratios following 95% CI in the fourth and fifth column. 
 
Candidate factors p= Hazard Ratio 95% CI 
Lower Upper 
BMI (>35 kg/m2) 0.448 1.8 0.4 7.9 
primary tumor (lung cancer, RCC or CUP)  0.225 1.7 0.7 4.3 
dexamethasone intake 0.046 2.3 1.1 5.0 
chemotherapy after BM diagnosis 0.146 2.0 0.8 4.8 
immobilization 0.001 6.2 2.7 14.2 
